An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DermTech (NASDAQ: DMTK) will hold a conference call on May 3, 2022, at 5:00 p.m. ET to discuss its first-quarter 2022 results. The company will also release its earnings press release prior to the call. Participants can join via U.S. toll-free number 844-467-7114 or international number 409-231-2086 using Conference ID: 6584229. DermTech aims to transform dermatology through its non-invasive skin genomics platform, focusing on early skin cancer detection and personalized treatment strategies.
Positive
DermTech is positioning itself as a leader in precision dermatology, which could enhance long-term growth potential.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Tuesday, May 3, 2022 at 5:00 p.m. Eastern Time (ET) to discuss the Company's first-quarter 2022 operating and financial highlights. In advance of the call on May 3, 2022, DermTech will issue its first-quarter 2022 earnings press release. To participate in the teleconference, callers can dial the following numbers:
844-467-7114 (toll-free, U.S.)
409-231-2086 (international)
Conference ID: 6584229
For those unable to participate in the live call and webcast, a webcast replay will be available on the Company’s website shortly after the conclusion of the call.
About DermTech:
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.
